Abstract:Abstract. Epigenetic modifications play an important role during carcinogenesis. The main goal of this study was to examine expression levels of two critical enzymes, DNA methyltransferase-1 (DNMT1) and histone deacetylase-1 (HDAC1), by immunohistochemistry (IHC) in human pancreatic cancer and precancerous lesions: 20 foci containing normal ductal epithelial cells without an inflammatory background (DE), 30 containing ductal epithelial cells with an inflammatory background (DEI), 48 of pancreatic intraepitheli… Show more
“…In addition, they observed decreased levels of DNA methylation at candidate genes in the normal pancreas of DNMT1 hypomorphic mice (86). Moreover, the expression of DNMT1 protein increased with the development of pancreatic cancer from normal tissue to precancerous lesions (PanINs) and to cancer (PDAC) (106–109). Clinic pathological analyses by Wang and colleagues suggested that PDAC patients with higher DNMT1 protein expression had an overall lower survival rate than those with lower expression.…”
Section: Pancreatic Cancermentioning
confidence: 99%
“…Clinic pathological analyses by Wang and colleagues suggested that PDAC patients with higher DNMT1 protein expression had an overall lower survival rate than those with lower expression. Moreover, higher DNMT1 expression correlated with advanced stages of the disease, reflecting the malignancy potential of PDAC (109). Recent studies examining DNMT mRNA expression in pancreatic cancer has also demonstrated that the levels of the three DNMTs increased with the development of pancreatic cancer from normal duct to pancreatic intraductal neoplasia and further to PDAC.…”
Cancer is the second leading cause of death in US. Despite the emergence of new, targeted agents, and the use of various therapeutic combinations, none of the available treatment options are curative in patients with advanced cancer. Epigenetic alterations are increasingly recognized as valuable targets for the development of cancer therapies. DNA methylation at the 5-position of cytosine, catalyzed by DNA methyltransferases (DNMTs), is the predominant epigenetic modification in mammals. DNMT1, the major enzyme responsible for maintenance of the DNA methylation pattern is located at the replication fork and methylates newly biosynthesized DNA. DNMT2 or TRDMT1, the smallest mammalian DNMT is believed to participate in the recognition of DNA damage, DNA recombination, and mutation repair. It is composed solely of the C-terminal domain, and does not possess the regulatory N-terminal region. The levels of DNMTs, especially those of DNMT3B, DNMT3A, and DNMT3L, are often increased in various cancer tissues and cell lines, which may partially account for the hypermethylation of promoter CpG-rich regions of tumor suppressor genes in a variety of malignancies. Moreover, it has been shown to function in self-renewal and maintenance of colon cancer stem cells and need to be studied in several cancers. Inhibition of DNMTs has demonstrated reduction in tumor formation in part through the increased expression of tumor suppressor genes. Hence, DNMTs can potentially be used as anti-cancer targets. Dietary phytochemicals also inhibit DNMTs and cancer stem cells; this represents a promising approach for the prevention and treatment of many cancers.
“…In addition, they observed decreased levels of DNA methylation at candidate genes in the normal pancreas of DNMT1 hypomorphic mice (86). Moreover, the expression of DNMT1 protein increased with the development of pancreatic cancer from normal tissue to precancerous lesions (PanINs) and to cancer (PDAC) (106–109). Clinic pathological analyses by Wang and colleagues suggested that PDAC patients with higher DNMT1 protein expression had an overall lower survival rate than those with lower expression.…”
Section: Pancreatic Cancermentioning
confidence: 99%
“…Clinic pathological analyses by Wang and colleagues suggested that PDAC patients with higher DNMT1 protein expression had an overall lower survival rate than those with lower expression. Moreover, higher DNMT1 expression correlated with advanced stages of the disease, reflecting the malignancy potential of PDAC (109). Recent studies examining DNMT mRNA expression in pancreatic cancer has also demonstrated that the levels of the three DNMTs increased with the development of pancreatic cancer from normal duct to pancreatic intraductal neoplasia and further to PDAC.…”
Cancer is the second leading cause of death in US. Despite the emergence of new, targeted agents, and the use of various therapeutic combinations, none of the available treatment options are curative in patients with advanced cancer. Epigenetic alterations are increasingly recognized as valuable targets for the development of cancer therapies. DNA methylation at the 5-position of cytosine, catalyzed by DNA methyltransferases (DNMTs), is the predominant epigenetic modification in mammals. DNMT1, the major enzyme responsible for maintenance of the DNA methylation pattern is located at the replication fork and methylates newly biosynthesized DNA. DNMT2 or TRDMT1, the smallest mammalian DNMT is believed to participate in the recognition of DNA damage, DNA recombination, and mutation repair. It is composed solely of the C-terminal domain, and does not possess the regulatory N-terminal region. The levels of DNMTs, especially those of DNMT3B, DNMT3A, and DNMT3L, are often increased in various cancer tissues and cell lines, which may partially account for the hypermethylation of promoter CpG-rich regions of tumor suppressor genes in a variety of malignancies. Moreover, it has been shown to function in self-renewal and maintenance of colon cancer stem cells and need to be studied in several cancers. Inhibition of DNMTs has demonstrated reduction in tumor formation in part through the increased expression of tumor suppressor genes. Hence, DNMTs can potentially be used as anti-cancer targets. Dietary phytochemicals also inhibit DNMTs and cancer stem cells; this represents a promising approach for the prevention and treatment of many cancers.
“…Pharmacological studies have shown that emodin exhibits anticancer effects in a number of human cancers (3). In addition, previous studies have shown that emodin exerts antiproliferative and apoptosis-inducing effects on cell lines derived from ovarian (4) and lung (5) cancer and leukemia (6). However, at present there is little information demonstrating the possible antiproliferative effect of emodin on colorectal cancer.…”
In this study, the effect of emodin and its mechanism of action were investigated in LOVO colorectal cancer cells. Cell growth was determined using a Cell Counting kit-8 assay, and the results demonstrated that emodin significantly inhibited the growth of LOVO cells in a concentration-dependent manner. In order to investigate the anticancer mechanism of emodin, reverse transcription polymerase chain reaction assays were performed to determine the B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X protein (Bax) expression ratio in LOVO colorectal cancer cells following treatment with emodin. The results showed that emodin induced a significant increase in the Bax expression level and a marked reduction of the Bcl-2 expression level in LOVO cells. In addition, emodin was found to have an inhibitory effect on the mitochondrial membrane potential and the results from the western blot analysis revealed that cytochrome c was released from the mitochondria to the cytoplasm. In combination, these results suggest that emodin inhibits cancer cell growth via the regulation of the Bcl-2/Bax ratio and by its effect on the mitochondrial apoptosis pathway.
“…Fluctuation of microtubule composition expression may lead to dynamic changes in microtubule and eventually alter the tumor response to paclitaxel. The increased expression levels of α-tubulin and βIII-tubulin, mutation of βI-tubulin or down-regulation of microtubule associated proteins (MAPs) can undermine the inherent stability of microtubules and reduce the efficacy of paclitaxel [51–52]. In this study, decreased mRNA and protein expressions of α-tubulin and βIII-tubulin in tumor tissues were detected in each treatment group except the control group.…”
Peptide hormone-based targeted therapy to tumors has been studied extensively. Our previous study shows that somatostatin receptor expresses high level on drug-resistant human ovarian cancer. The paclitaxel-octreotide conjugate (POC) exhibits enhanced growth inhibition, as well as reduced toxicity, in paclitaxel-resistant human ovarian cancer cells. The aim of this study was to investigate the effect of targeted cytotoxicity and potential reversal mechanism of resistance in paclitaxel-resistant human ovarian cancer cells xenografted into nude mice. The SSTR2 shows higher expression levels in tumor tissue. Moreover, fluorescein-labeled POC displays favorable targeting in tumor cells. POC presents the perfect efficacy in inhibiting tumor growth and exerts lower or no toxic effects on normal tissues. Real-time PCR and Western Blotting has demonstrated that the mRNA and protein expressions of SSTR2 in POC group were significantly higher, while MDR1, α-tubulin, βIII-tubulin, VEGF and MMP-9 were significantly lower than in the other treatment groups and controls. Combined with the previous study in vitro, this study evaluates an effective approach on the treatment of paclitaxel-resistant ovarian cancer which expresses somatostatin receptor SSTR. Our investigation has also revealed the possible molecular mechanism of POC in treating the ovarian cancer, and therefore, provided a theoretical basis for the clinical application of this newly-invented compound.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.